CD36 and neoplasm: CD36 was the first TSP1 receptor identified to mediate its anti-angiogenic activity [35], and peptide mimetic drugs derived from a sequence in the second TSR repeat of TSP1 that binds to CD36 (Figure 1) have been developed to inhibit tumor angiogenesis [43].